我要投票 九芝堂在阿胶行业中的票数:337
· 外 推 电 报 ·
2025-03-29 03:09:54 星期六

【九芝堂是哪个国家的品牌?】

九芝堂是什么牌子?「九芝堂」是 九芝堂股份有限公司 旗下著名品牌。该品牌发源于湖南省长沙市,由创始人李振国在1999-05-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力九芝堂品牌出海!通过在本页面挂载九芝堂品牌的产品链接和联系邮箱,可以提高九芝堂产品曝光!跨境电商爆单神器,目前只要100元/年哦~

九芝堂股份有限公司是国家重点中药企业,国内A股上市公司,湖南省重点高新技术企业,湖南省百强企业,湖南省质量管理奖企业,长沙市工业十大标志性工程龙头企业,国家博士后科研工作站企业。

九芝堂前身“劳九芝堂药铺”创建于1650年。2004年2月,“九芝堂”商标被国家工商行政管理总局商标局认定为中国驰名商标;2006年9月,“九芝堂”被国家商务部认定为“中华老字号”;2008年6月,九芝堂传统中药文化被列入国家级非物质文化遗产保护目录。

截至2009年底,公司已发展成为拥有总资产15.48亿元,净资产12.57亿元,下辖7家直接控股子公司、3家间接控股子公司,1家分公司,年销售过12亿元,利税过3亿元的工商一体化的现代大型医药企业。

公司主要从事补血系列、补益系列、肝炎系列等中药以及调节人体免疫力的生物制剂的生产与销售,正在形成销售过亿产品、过千万产品、迅速成长产品构成的一个产品阶梯,为可持续发展奠定了产品基础。主导产品驴胶补血颗粒年销售收入超过3亿元,位于全国天然补血类产品销售前三名;以六味地黄丸为代表的浓缩丸系列销售收入突破2亿元,位于全国同种产品销售前三名;斯奇康注射液销售收入1亿元。公司的中成药片剂、浓缩丸系列产品等出口欧美、日本、东南亚等地区,其中十多种浓缩丸、片剂出口日本已将近20年。九芝堂的产品不仅是济世良药,也是一种文化载体,九芝堂人不仅是客商,也成为了文化使节。

公司综合经济实力在湖南省医药行业中排名第一,已成为湖南省“十一五”重点发展的现代中药及生物医药优势产业集群的核心企业。2006年8月,在“首届中华老字号品牌价值百强榜”上,九芝堂以13.55亿的品牌价值排在第13位。2007年4月,九芝堂被《医药经济报》评为“中国制药工业企业百强”。2008年12月,公司通过湖南省科学技术厅的再认定,蝉联“高新技术企业”称号。

“九州共济、芝兰同芳”,面对激烈的市场竞争,九芝堂谋求和谐合作,共同发展。九芝堂将秉承三百多年优良的制药传统,把自主创新作为推动公司可持续发展的主导力量,立足民生、民情,发展现代中药产业,适度介入生物制品,开发消费者最为需要的产品,改善人类健康生活,致力于成为百亿市值企业。

英文翻译:Jiuzhitang Co., Ltd. is a national key traditional Chinese medicine enterprise, A-share listed company in China, key high-tech enterprise in Hunan Province, top 100 enterprise in Hunan Province, quality management award enterprise in Hunan Province, ten leading industrial engineering enterprises in Changsha City, and National Postdoctoral Research Station enterprise. The predecessor of Jiuzhitang, laojiuzhitang pharmacy, was founded in 1650. In February 2004, the trademark of "Jiuzhitang" was recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and commerce; in September 2006, the trademark of "Jiuzhitang" was recognized as a "Chinese time-honored brand" by the Ministry of Commerce; in June 2008, the traditional Chinese medicine culture of Jiuzhitang was listed in the national intangible cultural heritage protection catalogue. By the end of 2009, the company has developed into a modern large-scale pharmaceutical enterprise with total assets of 1.548 billion yuan and net assets of 1.257 billion yuan. It has seven directly controlled subsidiaries, three indirectly controlled subsidiaries and one branch, with annual sales of 1.2 billion yuan and profits and taxes of 300 million yuan. The company is mainly engaged in the production and sales of traditional Chinese medicine such as blood tonic series, tonic series, hepatitis series and biological preparations regulating human immunity. It is forming a product ladder consisting of over 100 million products, over 10 million products and rapidly growing products, laying a product foundation for sustainable development. The annual sales revenue of lvjiao Buxue granules, the leading product, is more than 300 million yuan, which is located in the top three sales of natural Buxue products in China; the sales revenue of concentrated pill series represented by Liuwei Dihuang pill is more than 200 million yuan, which is located in the top three sales of the same kind of products in China; the sales revenue of Siqikang injection is 100 million yuan. The company's Chinese patent medicine tablets and concentrated pill series products are exported to Europe, America, Japan, Southeast Asia and other regions, among which more than ten kinds of concentrated pills and tablets have been exported to Japan for nearly 20 years. Jiuzhitang's products are not only good medicine for the world, but also a cultural carrier. Jiuzhitang people are not only merchants, but also cultural envoys. The company's comprehensive economic strength ranks first in the pharmaceutical industry of Hunan Province, and it has become the core enterprise of modern Chinese medicine and biomedical industry cluster which is the key development of "11th Five Year Plan" in Hunan Province. In August 2006, Jiuzhitang ranked 13th in the "top 100 list of brand value of the first time-honored Chinese brands". In April 2007, Jiuzhitang was named "top 100 pharmaceutical enterprises in China" by pharmaceutical economic news. In December 2008, the company passed the reappraisal of science and Technology Department of Hunan Province and won the title of "high and new technology enterprise". In the face of fierce market competition, Jiuzhitang seeks for harmonious cooperation and common development. Jiuzhitang will adhere to the excellent pharmaceutical tradition of more than three hundred years, take independent innovation as the leading force to promote the sustainable development of the company, based on the people's livelihood and the people's conditions, develop the modern Chinese medicine industry, moderately intervene in biological products, develop the products most needed by consumers, improve the healthy life of human beings, and strive to become a 10 billion market value enterprise.

本文链接: https://www.waitui.com/brand/7e3ceb284.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

融创中国:2024年收入约为740.2亿元,同比减少约52%

36氪获悉,融创中国公告,2024年收入约为740.2亿元,同比减少约52%;公司拥有人应占亏损约为257亿元,上年同期公司拥有人应占亏损约为79.7亿元。

2小时前

国泰君安:2024年净利润同比增长38.94%,拟每10股派2.8元

36氪获悉,国泰君安公告,2024年实现营业收入433.97亿元,同比增长20.08%;归母净利润130.24亿元,同比增长38.94%。公司拟每10股派发现金红利2.8元(含税)。

2小时前

美股大型科技股盘前多数下跌,亚马逊跌超1%

36氪获悉,美股大型科技股盘前多数下跌,截至发稿,亚马逊跌超1%,苹果跌0.89%,微软跌0.72%,谷歌跌0.62%,Meta跌0.59%,奈飞跌0.26%,特斯拉涨超1%,英伟达涨0.02%。

2小时前

热门中概股美股盘前普跌,多股跌超2%

36氪获悉,热门中概股美股盘前普跌,截至发稿,京东、百度、哔哩哔哩、小鹏汽车、蔚来跌超2%,阿里巴巴、拼多多、理想汽车跌超1%。

2小时前

苏宁易购:2024年盈利6.1亿元,同比增114.93%

36氪获悉,苏宁易购发布2024年度报告,公司全年实现归属于上市公司股东的净利润6.1亿元,同比增长114.93%,经营活动产生的现金流量净额45.86亿元,同比增长57.56%,自2020年以来首次实现全年盈利。其中,四季度门店销售规模同比增长64.6%,零售服务商战略深化显效。

2小时前

本页详细列出关于东健阿胶的品牌信息,含品牌所属公司介绍,东健阿胶所处行业的品牌地位及优势。
咨询